These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 3839263)

  • 1. A controlled evaluation of combined 5-fluorouracil, doxorubicin, and mitomycin C (FAM) for the treatment of advanced non-small-cell lung cancer.
    Krook JE; Jett JR; Fleming TR; Dalton RJ; Marschke RF; Cullinan SA; Windschitl HE; Everson LK; Brunk FS; Laurie JA
    J Clin Oncol; 1985 Jun; 3(6):842-8. PubMed ID: 3839263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin.
    Cullinan SA; Moertel CG; Fleming TR; Rubin JR; Krook JE; Everson LK; Windschitl HE; Twito DI; Marschke RF; Foley JF
    JAMA; 1985 Apr; 253(14):2061-7. PubMed ID: 2579257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combination of cisplatin, doxorubicin, and mitomycin (PAM) compared with the FAM regimen in treating advanced gastric carcinoma. A phase II randomized trial of the Italian Oncology Group for Clinical Research.
    De Lisi V; Cocconi G; Angelini F; Cavicchi F; Di Costanzo F; Gilli G; Rodinò C; Soldani M; Tonato M; Finardi C
    Cancer; 1996 Jan; 77(2):245-50. PubMed ID: 8625230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B.
    Chahinian AP; Propert KJ; Ware JH; Zimmer B; Perry MC; Hirsh V; Skarin A; Kopel S; Holland JF; Comis RL
    J Clin Oncol; 1989 Aug; 7(8):993-1002. PubMed ID: 2547030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclophosphamide versus 5-fluorouracil, doxorubicin, and mitomycin C (FAM') in the treatment of hormone-resistant metastatic carcinoma of the prostate: a preliminary report of a randomized trial.
    Kasimis BS; Miller JB; Kaneshiro CA; Forbes KA; Moran EM; Metter GE
    J Clin Oncol; 1985 Mar; 3(3):385-92. PubMed ID: 3838343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. The Gastrointestinal Tumor Study Group.
    J Clin Oncol; 1986 Dec; 4(12):1794-8. PubMed ID: 2946815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy in advanced adenocarcinoma of the lung: comparison of two dosage schedules.
    Lam WK; So SY; Kung TM; Sham MK; Ip M
    Cancer Chemother Pharmacol; 1987; 19(3):269-71. PubMed ID: 3107849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination chemotherapy in metastatic tumors of unknown origin. 5-Fluorouracil, adriamycin and mitomycin C for adenocarcinomas and adriamycin, vinblastine and mitomycin C for anaplastic carcinomas.
    Sulkes A; Uziely B; Isacson R; Brufman G; Biran S
    Isr J Med Sci; 1988; 24(9-10):604-10. PubMed ID: 3204009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-Fluorouracil, doxorubicin, and mitomycin-C in the treatment of adenocarcinoma and large cell carcinoma of the lung.
    Shaw MT; Shaw MK
    Cancer; 1987 Sep; 60(6):1190-3. PubMed ID: 3040207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized comparative trial of sequential versus alternating cyclophosphamide, doxorubicin, and cisplatin and mitomycin, lomustine, and methotrexate in metastatic non-small-cell lung cancer.
    Eagan RT; Frytak S; Richardson RL; Creagan ET; Therneau TM; Coles DT; Jett JR
    J Clin Oncol; 1988 Jan; 6(1):5-8. PubMed ID: 2826714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ftorafur, adriamycin and mitomycin C (FAM II) for extensive bronchogenic adenocarcinoma and large cell carcinoma.
    Salvati F; Cruciani AR; De Marinis A; Nunziati F; Portalone L
    Jpn J Clin Oncol; 1984 Mar; 14(1):3-6. PubMed ID: 6323790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM).
    Oster MW; Gray R; Panasci L; Perry MC
    Cancer; 1986 Jan; 57(1):29-33. PubMed ID: 2934124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary.
    Goldberg RM; Smith FP; Ueno W; Ahlgren JD; Schein PS
    J Clin Oncol; 1986 Mar; 4(3):395-9. PubMed ID: 3754004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Combination chemotherapy with etoposide, mitomycin C, and cyclophosphamide in advanced non-small cell lung cancer].
    Homma T; Yoneda S; Fukuda Y; Nakata M; Noguchi Y; Yoshida S
    Gan To Kagaku Ryoho; 1986 Jul; 13(7):2399-403. PubMed ID: 3015045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of methotrexate-FAM (m-FAM) in adenocarcinoma of unknown primary.
    Treat J; Falchuk SC; Tremblay C; Spielman M; Woolley PV; Rouesse J; Sevin D; Le Chevalier T
    Eur J Cancer Clin Oncol; 1989 Jul; 25(7):1053-5. PubMed ID: 2759160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil.
    Laurie JA; Hahn RG; Therneau TM; Patel SR; Mailliard JA; Windschitl HE; Twito DI; Morton RF; Krook JE
    Cancer; 1992 Mar; 69(6):1440-4. PubMed ID: 1540881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FAM (5-fluorouracil, doxorubicin, and mitomycin) plus triazinate (FAM-T) in gastric carcinoma: a combined phase II trial of the Mid-Atlantic Oncology Program and the Pan American Health Organization.
    Ahlgren JD; Smith FP; Cazap E; Estevez RA; Marantz A; Woolley PV; Wilcosky T; Stein J; Schein PS
    Cancer Treat Rep; 1987 Apr; 71(4):419-20. PubMed ID: 3548959
    [No Abstract]   [Full Text] [Related]  

  • 18. Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research.
    Cocconi G; Bella M; Zironi S; Algeri R; Di Costanzo F; De Lisi V; Luppi G; Mazzocchi B; Rodinò C; Soldani M
    J Clin Oncol; 1994 Dec; 12(12):2687-93. PubMed ID: 7989945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of platinum-based regimens in non-small cell lung cancer. A negative report from the Cuneo Lung Cancer Study Group.
    Buccheri G; Ferrigno D
    Lung Cancer; 1997 Aug; 18(1):57-70. PubMed ID: 9268948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant chemotherapy with 5-fluorouracil, doxorubicin and mitomycin-C (FAM) for 6 months after curative resection of gastric carcinoma.
    Koo DH; Lee JL; Kim TW; Chang HM; Ryu MH; Yook JH; Oh ST; Kim BS; Lee JS; Kang YK
    Eur J Surg Oncol; 2007 Sep; 33(7):843-8. PubMed ID: 17207959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.